Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyxeos and Quizartinib in R/R FLT3-ITD AML
NCT04209725Phase 2Terminated
- Sponsor
- SCRI Development Innovations
- Start
- Jun 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of quizartinib in acute myeloid leukemia (AML), sponsored by SCRI Development Innovations. Started Jun 2020; status: terminated.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04209725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209725.